Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial

Akihiro Ito(Tohoku University), Yoichi Arai(Japan Atomic Energy Agency), Ichiro Shintaku(Sendai Shakai Hoken Hospital), Naomasa Ioritani(Sendai Shakai Hoken Hospital), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Hiroshi Aoki(Nippon Veterinary and Life Science University), Kazuhiko Orikasa(Sendai Shakai Hoken Hospital), Atsushi Kyan(Sendai Shakai Hoken Hospital), Shigeto Ishidoya(Sendai City Hospital), Takuhiro Yamaguchi(Tohoku University), Makoto Satoh(William S. Middleton Memorial Veterans Hospital), Takashige Namima(Japan Organization of Occupational Health and Safety), Atsushi Takeda(Tohoku University), Hisanobu Adachi(Sendai Shakai Hoken Hospital), Shunichi Namiki(Sendai Shakai Hoken Hospital), Shinnosuke Katoh(Sendai Shakai Hoken Hospital), Yoshihiro Ikeda(Kyoto Medical Center), Tatsuo Tochigi(Miyagi Prefectural Hospital Organization), Masataka Aizawa(Sendai Shakai Hoken Hospital), Satoru Tokuyama(Miyagi Prefectural Hospital Organization), Isao Numata(Tohoku University), Seıjı Ueno(Tohoku University), Koichi Kambe(Sendai Shakai Hoken Hospital)
Journal of Clinical Oncology
March 5, 2013
Cited by 253


Related Papers